Ready-Made immune cells take on Hard-to-Treat cancers

NCT ID NCT06241456

Recruiting now Disease control Sponsor: Fate Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 study tests an experimental therapy called FT825, a type of immune cell that is made in a lab and can be given to any patient without needing to use their own cells. It is being tested in people with advanced solid tumors that have HER2 or other markers. The study will check safety and whether the cells can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FT825 (an off-the-shelf CAR T-cell therapy)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong: This is an early phase 1 trial focused on safety, so it is not yet known if FT825 will shrink tumors. Side effects from the therapy and chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Banner MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
OU Health Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Ohio State University - Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Oncology Hematology Care Clinial Trials
RECRUITING

Cincinnati, Ohio, 45242, United States
Sarah Cannon Research Institute (SCRI) - Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of California San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92037, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Minnesota Medical School
RECRUITING

Minneapolis, Minnesota, 55455, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
Yale New Haven Hospital - Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.